After reports from India about several children’s deaths following the use of a cough medicine called “Coldrif,” public concern has grown sharply. To answer whether this medicine exists in Uzbekistan, the Center for Pharmaceutical Product Safety issued an official statement.
According to the Center, the drug “Coldrif,” manufactured by the company “Sresan Pharma,” is not registered in the Republic of Uzbekistan. This means that the medicine is not officially authorized for sale or medical use in the country.
Medical experts emphasize that any medication can only be used after official state registration. This requirement is strictly defined by the Law of the Republic of Uzbekistan “On Medicines and Pharmaceutical Activities.”
For reference: the incident in the Indian state of Haryana has drawn the attention of the global medical community. Reports indicate that 14 children died after taking “Coldrif” syrup. Laboratory tests revealed that the medicine may contain highly toxic substances — diethylene glycol or ethylene glycol.
Following the tragedy, several countries decided to withdraw the company’s products from the market or temporarily ban them.
Uzbekistan’s authorities promptly conducted an inspection and confirmed that “Sresan Pharma” products are not registered in Uzbekistan and are not distributed through pharmacies.
The Center for Pharmaceutical Safety urged citizens to avoid unknown or internet-sourced medicines and to use only officially registered and licensed drugs.
Thus, the “Coldrif” situation once again proves that caution and reliance on official sources when choosing medicines are vital to human life.
Read “Zamin” on Telegram!
